NCT07252141 is a clinical trial in Systemic Lupus Erythematosus (SLE), sponsored by Eman Mohamed Shawky.

Who is sponsoring NCT07252141?

NCT07252141 is sponsored by Eman Mohamed Shawky.

What condition does NCT07252141 study?

NCT07252141 studies Systemic Lupus Erythematosus (SLE).

Is NCT07252141 still recruiting?

NCT07252141 is currently not yet recruiting. Last updated 26 November 2025.

Last reviewed 2025-11-26 · How we verify

NCT07252141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

miR-101-3p and Autotaxin in SLE Patients

Not yet recruiting Last updated 26 November 2025

What this trial tests

trial in Systemic Lupus Erythematosus (SLE) in 40 participants. Not yet recruiting.

Timeline

30 December 2025

Primary endpoint
30 June 2026

30 July 2026

Quick facts

Lead sponsor	Eman Mohamed Shawky
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	40
Start date	30 December 2025
Primary completion	30 June 2026
Estimated completion	30 July 2026

Conditions studied

Systemic Lupus Erythematosus (SLE) — all drugs for Systemic Lupus Erythematosus (SLE) →

Sponsor

Eman Mohamed Shawky

Who can join

18 and older, any sex, with Systemic Lupus Erythematosus (SLE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organs and characterized by heterogeneous clinical manifestations. This case-control study aims to assess the association between serum expression levels of MicroRNA-101-3p and Autotaxin (ATX) in SLE patients compared with healthy controls. The hypothesis is that dysregulation of miR-101-3p and ATX contributes to SLE pathogenesis and may serve as potential non-invasive biomarkers for disease activity and prognosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Systemic Lupus Erythematosus (SLE)

Currently open trials in the same condition.

NCT07447986 — To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus · Phase 2 · recruiting
NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
NCT06875960 — A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07252141 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eman Mohamed Shawky
Last refreshed: 26 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07252141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing